Is Chromocell Therapeutics Stock a Good Investment?
Chromocell Therapeutics Investment Advice | CHRO |
- Examine Chromocell Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Chromocell Therapeutics' leadership team and their track record. Good management can help Chromocell Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Chromocell Therapeutics' business and its evolving consumer preferences.
- Compare Chromocell Therapeutics' performance and market position to its competitors. Analyze how Chromocell Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Chromocell Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Chromocell Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Chromocell Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Chromocell Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Good | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Chromocell Therapeutics Stock
Researching Chromocell Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 76.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.68. Chromocell Therapeutics had not issued any dividends in recent years.
To determine if Chromocell Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Chromocell Therapeutics' research are outlined below:
| Chromocell Therapeutics is way too risky over 90 days horizon | |
| Chromocell Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (7.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Chromocell Therapeutics generates negative cash flow from operations | |
| Chromocell Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 76.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Zentalis Pharmaceuticals, Inc. Short Interest Update - Defense World |
Chromocell Therapeutics Quarterly Cash And Short Term Investments |
|
Chromocell Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.34 M.Market Cap |
|
Chromocell Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (88.06) | (92.46) | |
| Return On Capital Employed | 0.96 | 0.48 | |
| Return On Assets | (88.06) | (92.46) | |
| Return On Equity | 1.03 | 1.08 |
Determining Chromocell Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Chromocell Therapeutics is a good buy. For example, gross profit margin measures Chromocell Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Chromocell Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Chromocell Stock
As of the 2nd of February, Chromocell Therapeutics shows the Risk Adjusted Performance of 0.1548, downside deviation of 8.59, and Mean Deviation of 8.03. Chromocell Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Chromocell Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chromocell Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chromocell Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chromocell Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Friedberg Ezra M over two months ago Acquisition by Friedberg Ezra M of 24533 shares of Chromocell Therapeutics at 0.64 subject to Rule 16b-3 | ||
Francis Knuettel Ii over three months ago Acquisition by Francis Knuettel Ii of 3500 shares of Chromocell Therapeutics at 0.97 subject to Rule 16b-3 | ||
Francis Knuettel Ii over three months ago Acquisition by Francis Knuettel Ii of 6500 shares of Chromocell Therapeutics at 0.89 subject to Rule 16b-3 | ||
Ame Equities Llc over six months ago CHROMOCELL THERAPEUTICS exotic insider transaction detected | ||
Davis Todd C over six months ago Exercise or conversion by Davis Todd C of 29167 shares of CHROMOCELL THERAPEUTICS subject to Rule 16b-3 | ||
Ame Equities Llc over six months ago CHROMOCELL THERAPEUTICS exotic insider transaction detected |
Understand Chromocell Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Chromocell Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1548 | |||
| Market Risk Adjusted Performance | 1.03 | |||
| Mean Deviation | 8.03 | |||
| Semi Deviation | 6.74 | |||
| Downside Deviation | 8.59 | |||
| Coefficient Of Variation | 577.17 | |||
| Standard Deviation | 15.13 | |||
| Variance | 229.01 | |||
| Information Ratio | 0.1681 | |||
| Jensen Alpha | 2.44 | |||
| Total Risk Alpha | 1.37 | |||
| Sortino Ratio | 0.296 | |||
| Treynor Ratio | 1.02 | |||
| Maximum Drawdown | 110.46 | |||
| Value At Risk | (12.68) | |||
| Potential Upside | 17.95 | |||
| Downside Variance | 73.84 | |||
| Semi Variance | 45.47 | |||
| Expected Short fall | (10.77) | |||
| Skewness | 4.13 | |||
| Kurtosis | 24.36 |
| Risk Adjusted Performance | 0.1548 | |||
| Market Risk Adjusted Performance | 1.03 | |||
| Mean Deviation | 8.03 | |||
| Semi Deviation | 6.74 | |||
| Downside Deviation | 8.59 | |||
| Coefficient Of Variation | 577.17 | |||
| Standard Deviation | 15.13 | |||
| Variance | 229.01 | |||
| Information Ratio | 0.1681 | |||
| Jensen Alpha | 2.44 | |||
| Total Risk Alpha | 1.37 | |||
| Sortino Ratio | 0.296 | |||
| Treynor Ratio | 1.02 | |||
| Maximum Drawdown | 110.46 | |||
| Value At Risk | (12.68) | |||
| Potential Upside | 17.95 | |||
| Downside Variance | 73.84 | |||
| Semi Variance | 45.47 | |||
| Expected Short fall | (10.77) | |||
| Skewness | 4.13 | |||
| Kurtosis | 24.36 |
Consider Chromocell Therapeutics' intraday indicators
Chromocell Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Chromocell Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Chromocell Therapeutics Corporate Filings
| 15th of January 2025 Other Reports | ViewVerify | |
| 11th of December 2024 Other Reports | ViewVerify | |
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 19th of November 2024 Other Reports | ViewVerify |
Chromocell Stock media impact
Far too much social signal, news, headlines, and media speculation about Chromocell Therapeutics that are available to investors today. That information is available publicly through Chromocell media outlets and privately through word of mouth or via Chromocell internal channels. However, regardless of the origin, that massive amount of Chromocell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Chromocell Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Chromocell Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Chromocell Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Chromocell Therapeutics alpha.
Chromocell Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Chromocell Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether Chromocell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chromocell Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chromocell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chromocell Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromocell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Chromocell Stock, please use our How to Invest in Chromocell Therapeutics guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromocell Therapeutics. If investors know Chromocell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromocell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chromocell Therapeutics is measured differently than its book value, which is the value of Chromocell that is recorded on the company's balance sheet. Investors also form their own opinion of Chromocell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chromocell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromocell Therapeutics' market value can be influenced by many factors that don't directly affect Chromocell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Chromocell Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Chromocell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromocell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.